Two serum biomarkers (CCL11/eotaxin, IL-6) discriminate between CRMO, alternative diagnoses (acute leukemia, lymphoma, JIA, osteoarticular infections, and reactive or para-infectious arthritis), and healthy controls. The gene discussed is IL6; the disease is juvenile idiopathic arthritis.